Saag M - Search Results

1

Immunization costs and programmatic barriers at an urban HIV clinic.

Eaton EF, Kulczycki A, Saag M, Mugavero M, Raper JL. Eaton EF, et al. Among authors: saag m. Clin Infect Dis. 2015 Dec 1;61(11):1726-31. doi: 10.1093/cid/civ637. Epub 2015 Jul 29. Clin Infect Dis. 2015. PMID: 26224001 Free PMC article.

2

Prolonged suppression of human immunodeficiency virus type 1 RNA during dual nucleoside reverse-transcriptase-inhibitor therapy in clinical practice.

Hoesley CJ, Saag MS, Chatham A, Kilby JM. Hoesley CJ, et al. Among authors: saag ms. Clin Infect Dis. 2000 Oct;31(4):1095-7. doi: 10.1086/318143. Clin Infect Dis. 2000. PMID: 11049795

3

Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection.

Call SA, Saag MS, Westfall AO, Raper JL, Pham SV, Tolson JM, Hellmann NS, Cloud GA, Johnson VA. Call SA, et al. Among authors: saag ms. J Infect Dis. 2001 Feb 1;183(3):401-8. doi: 10.1086/318078. Epub 2000 Dec 29. J Infect Dis. 2001. PMID: 11133371

4

Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases.

Coghlan ME, Sommadossi JP, Jhala NC, Many WJ, Saag MS, Johnson VA. Coghlan ME, et al. Among authors: saag ms. Clin Infect Dis. 2001 Dec 1;33(11):1914-21. doi: 10.1086/323783. Epub 2001 Oct 24. Clin Infect Dis. 2001. PMID: 11692304

5

Immunologic and virologic consequences of temporary antiretroviral treatment interruption in clinical practice.

Chen RY, Westfall AO, Raper JL, Cloud GA, Chatham AK, Acosta EP, Pham SV, Tolson JM, Heudebert GR, Saag MS. Chen RY, et al. Among authors: saag ms. AIDS Res Hum Retroviruses. 2002 Sep 1;18(13):909-16. doi: 10.1089/088922202760265588. AIDS Res Hum Retroviruses. 2002. PMID: 12230934

6

Duration of highly active antiretroviral therapy regimens.

Chen RY, Westfall AO, Mugavero MJ, Cloud GA, Raper JL, Chatham AG, Acosta EP, Taylor KH, Carter J, Saag MS. Chen RY, et al. Clin Infect Dis. 2003 Sep 1;37(5):714-22. doi: 10.1086/377271. Epub 2003 Aug 13. Clin Infect Dis. 2003. PMID: 12942406

7

Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002.

Bedimo R, Chen RY, Accortt NA, Raper JL, Linn C, Allison JJ, Dubay J, Saag MS, Hoesley CJ. Bedimo R, et al. Clin Infect Dis. 2004 Nov 1;39(9):1380-4. doi: 10.1086/424883. Epub 2004 Oct 11. Clin Infect Dis. 2004. PMID: 15494916

8

Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.

Saag MS. Saag MS. Clin Infect Dis. 2006 Jan 1;42(1):126-31. doi: 10.1086/498348. Epub 2005 Nov 23. Clin Infect Dis. 2006. PMID: 16323102 Review.

9

Sustained HIV viral suppression following treatment interruption: an observational study.

Bedimo R, Chen RY, Westfall AO, Raper JL, Allison JJ, Saag MS. Bedimo R, et al. AIDS Res Hum Retroviruses. 2006 Jan;22(1):40-4. doi: 10.1089/aid.2006.22.40. AIDS Res Hum Retroviruses. 2006. PMID: 16438644

10

Ethnic variations in the prevalence of metabolic bone disease among HIV-positive patients with lipodystrophy.

Curtis JR, Smith B, Weaver M, Landers K, Lopez-Ben R, Raper JL, Saag M, Venkataraman R, Saag KG. Curtis JR, et al. Among authors: saag m, saag kg. AIDS Res Hum Retroviruses. 2006 Feb;22(2):125-31. doi: 10.1089/aid.2006.22.125. AIDS Res Hum Retroviruses. 2006. PMID: 16478393

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

599 results

Search Page

Filters